Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2022 | The challenges associated with long-term TKI use in patients with CML

Mhairi Copland • 29 Sep 2022

SOHO 2022

Chronic Myeloid Leukemia Leukemia Imatinib Nilotinib Ponatinib

BYOND DESTINY

Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, shares some insights into the challenges associated with the long-term use of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML) and strategies to overcome these. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals.

Current and future treatment strategies for blast-phase CML

Mhairi Copland • 29 Sep 2022

The importance of improving treatment-free remission in patients with CML

Mhairi Copland • 29 Sep 2022

Treatment options for patients with CML

Mhairi Copland • 29 Sep 2022

Novel therapeutic for AML: CYC065 combinations

Mhairi Copland • 7 Dec 2019

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024